BioMarin Reports Strong Revenue, Acquires Amicus

BioMarin Pharmaceutical reported fiscal Q4 and full-year 2025 results on February 23, with full-year revenues rising 13% to $3.2 billion and Q4 revenues up 17% year‑over‑year; VOXZOGO revenue grew 26% for the year and 31% in Q4 while enzyme therapies rose 9% and 13%, respectively. On February 25 Bernstein raised its price target to $94 and maintained an Outperform, and BioMarin announced a definitive agreement to acquire Amicus Therapeutics, expected to accelerate and diversify revenues.